260 related articles for article (PubMed ID: 17239011)
21. The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared mechanism of injury in primary-progressive MS.
Pardini M; Petracca M; Harel A; Fleysher L; Oesingmann N; Bommarito G; Fabian M; Chard D; Lublin F; Inglese M
Neuroimage Clin; 2017; 16():111-115. PubMed ID: 28794971
[TBL] [Abstract][Full Text] [Related]
22. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis.
Plumb J; McQuaid S; Mirakhur M; Kirk J
Brain Pathol; 2002 Apr; 12(2):154-69. PubMed ID: 11958369
[TBL] [Abstract][Full Text] [Related]
23. Water content and myelin water fraction in multiple sclerosis. A T2 relaxation study.
Laule C; Vavasour IM; Moore GR; Oger J; Li DK; Paty DW; MacKay AL
J Neurol; 2004 Mar; 251(3):284-93. PubMed ID: 15015007
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study.
Yaldizli Ö; Pardini M; Sethi V; Muhlert N; Liu Z; Tozer DJ; Samson RS; Wheeler-Kingshott CA; Yousry TA; Miller DH; Chard DT
Mult Scler; 2016 Feb; 22(2):150-9. PubMed ID: 26014608
[TBL] [Abstract][Full Text] [Related]
25. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
[TBL] [Abstract][Full Text] [Related]
26. (1)H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis.
Caramanos Z; DiMaio S; Narayanan S; Lapierre Y; Arnold DL
J Neurol Sci; 2009 Jul; 282(1-2):72-9. PubMed ID: 19232641
[TBL] [Abstract][Full Text] [Related]
27. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
28. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
[TBL] [Abstract][Full Text] [Related]
29. Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis.
Wolswijk G; Balesar R
Brain; 2003 Jul; 126(Pt 7):1638-49. PubMed ID: 12805111
[TBL] [Abstract][Full Text] [Related]
30. Cognitive impairment in primary and secondary progressive multiple sclerosis.
Wachowius U; Talley M; Silver N; Heinze HJ; Sailer M
J Clin Exp Neuropsychol; 2005 Jan; 27(1):65-77. PubMed ID: 15814443
[TBL] [Abstract][Full Text] [Related]
31. [Assessment of decision-making capacity in primary and secondary progressive multiple sclerosis].
García-Molina A; Enseñat-Cantallops A; Sánchez-Carrión R; Roig-Rovira T
Neurologia; 2009 Mar; 24(2):94-7. PubMed ID: 19322686
[TBL] [Abstract][Full Text] [Related]
32. Multiple sclerosis as a generalized CNS disease--comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS.
Lindberg RL; De Groot CJ; Certa U; Ravid R; Hoffmann F; Kappos L; Leppert D
J Neuroimmunol; 2004 Jul; 152(1-2):154-67. PubMed ID: 15223248
[TBL] [Abstract][Full Text] [Related]
33. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
[TBL] [Abstract][Full Text] [Related]
34. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.
Lassmann H
Front Immunol; 2018; 9():3116. PubMed ID: 30687321
[TBL] [Abstract][Full Text] [Related]
35. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
[TBL] [Abstract][Full Text] [Related]
36. Altered maturation of circulating dendritic cells in primary progressive MS patients.
López C; Comabella M; Al-zayat H; Tintoré M; Montalban X
J Neuroimmunol; 2006 Jun; 175(1-2):183-91. PubMed ID: 16698091
[TBL] [Abstract][Full Text] [Related]
37. Accumulation of cortical lesions in MS: relation with cognitive impairment.
Roosendaal SD; Moraal B; Pouwels PJ; Vrenken H; Castelijns JA; Barkhof F; Geurts JJ
Mult Scler; 2009 Jun; 15(6):708-14. PubMed ID: 19435749
[TBL] [Abstract][Full Text] [Related]
38. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis.
Vos CM; Geurts JJ; Montagne L; van Haastert ES; Bö L; van der Valk P; Barkhof F; de Vries HE
Neurobiol Dis; 2005 Dec; 20(3):953-60. PubMed ID: 16039866
[TBL] [Abstract][Full Text] [Related]
39. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
[TBL] [Abstract][Full Text] [Related]
40. T2 MRI texture analysis is a sensitive measure of tissue injury and recovery resulting from acute inflammatory lesions in multiple sclerosis.
Zhang Y; Zhu H; Mitchell JR; Costello F; Metz LM
Neuroimage; 2009 Aug; 47(1):107-11. PubMed ID: 19361563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
